BioPharmSignal logoBioPharmSignal

Biotech News

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Capricor Therapeutics (CAPR)Capricor TherapeuticsFDA / regulatory

CAPR (CAPR) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is capr.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-07-30 13:30 EST

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

MNPRMonopar2026-06-30 12:00 EST

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

PHVSPharvaris2026-07-06 10:50 EST

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

RAREUltragenyx Pharmaceutical2026-04-02 12:30 EST

Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

RAREUltragenyx Pharmaceutical2026-03-30 12:30 EST

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

BIIBBiogen2026-07-13 21:38 EST

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

AGIOAgios Pharmaceuticals, Inc.2026-07-07 11:00 EST

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

BIIBBiogen2026-06-04 11:30 EST

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

ETONEton Pharmaceuticals2026-05-19 20:30 EST

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

View all latest news

Capricor Therapeutics

Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Deramiocel The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling. HOPE-3 Evidence The...

Recent company news

CAPRCapricor Therapeutics2026-07-30 13:30 EST

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

CAPRCapricor Therapeutics2026-07-29 14:05 EST

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-07-27 15:00 EST

Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-06-26 13:05 EST

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Stock data

Close
4.18 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States